Immunotherapy revolutionized cancer care in the last decade and, notably among its tools, the programmed cell death protein-1 (PD-1) inhibitors.
Publications
Second-Line Treatment With Apatinib in Patients with Recurrent or Refractory Melanoma
According to Shumin Yuan and colleagues from the Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital in Zhengzhou, China, metastatic malignant melanoma is associated with very poor prognosis, partly due to resistance against conventional chemotherapies.
Does the morphology of cutaneous melanoma help explain the international differences in survival? Results from 1,578,482 adults diagnosed during 2000-2014 in 59 countries (CONCORD-3)
BACKGROUND: CONCORD-3 highlighted wide disparities in population-based 5-year net survival during 2000-2014. Clinical evidence suggests marked international differences in the proportion of lethal acral and nodular subtypes.
FDA Grants Fast Track Designation to 7HP349 for Anti-PD-1 Metastatic Melanoma
Fast track designation has been granted to 7HP349, in combination with a CTLA-4 inhibitor for the treatment of patients with unresectable or metastatic malignant melanoma following treatment failure with a PD-1 inhibitor.